Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission a randomized clinical trial

JAMA

Volumn 303, Issue 13, 2010, Pages 1266-1273

  Foell, Dirk ^a   Wulffraat, Nico ^b   Wedderburn, Lucy R ^c   Wittkowski, Helmut ^a   Frosch, Michael ^a   Gerß, Joachim ^a   Stanevicha, Valda ^d   Mihaylova, Dimitrina ^e   Ferriani, Virginia ^f   Tsakalidou, Florence Kanakoudi ^g   Foeldvari, Ivan ^h   Cuttica, Ruben ⁱ   Gonzalez, Benito ^j   Ravelli, Angelo ^k   Khubchandani, Raju ^l   Oliveira, Sheila ^m   Armbrust, Wineke ⁿ   Garay, Stella ^o   Vojinovic, Jelena ^p   Norambuena, Ximena ^q   Gamir, María Luz ^r   García Consuegra, Julia ^s   Lepore, Loredana ^t   Susic, Gordana ^u   Corona, Fabrizia ^v   Dolezalova, Pavla ^w   Pistorio, Angela ^x   Martini, Alberto ^k   Ruperto, Nicolino ^x   Roth, Johannes ^a   more..

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d RIGA STRADINS UNIVERSITY   (Latvia)

^e Clinic of Pediatric Nephrology   (Bulgaria)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h Kinder und Jugendrheumatologie   (Germany)

ⁱ HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^j HOSPITAL LUIS CALVO MACKENNA   (Chile)

^k UNIVERSITY OF GENOA   (Italy)

^l JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^m FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁿ UNIVERSITY OF GRONINGEN   (Netherlands)

^o Hospital de Ninos Sor Maria Ludovica   (Argentina)

^p University Clinical Center   (Serbia)

^q Pediatra Reumatólogo Unidad Inmuno Reumatología Hospital Dr Exequiel González Cortés   (Chile)

^r HOSPITAL RAMÓN Y CAJAL   (Spain)

^s HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^t UNIVERSITY OF TRIESTE   (Italy)

^u INSTITUTE OF RHEUMATOLOGY   (Serbia)

^v Fondazione Policlinico Mangiagalli Regina Elena   (Italy)

^w CHARLES UNIVERSITY   (Czech Republic)

^x G GASLINI INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; METHOTREXATE; ABC TRANSPORTER; ABCC11 PROTEIN, HUMAN; ANTIRHEUMATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; BLOOD; INFANT; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RECURRENT DISEASE;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; ATP-BINDING CASSETTE TRANSPORTERS; CALGRANULIN B; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; METHOTREXATE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION;

EID: 77950512831     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.375     Document Type: Article

References (30)

1. Giannini EH, Brewer EJ, Kuzmina N, et al; The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U. S. A.-U. S. S. R. double-blind, placebocontrolled trial. N Engl J Med. 1992;326(16):1043-1049.
2. Lovell DJ, Ruperto N, Goodman S, et al; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810-820.
3. Ruperto N, Murray KJ, Gerloni V, et al; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50(7):2191-2201.
4. Ruperto N, Ravelli A, Levinson JE, et al. Longterm health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis, II: early predictors of outcome. J Rheumatol. 1997;24(5):952-958. (Pubitemid 27223634)
5. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-2294.
6. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554-3562. (Pubitemid 41612224)
7. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis. J Rheumatol. 2006;33(4):789-795.
8. Wallace CA, Sherry DD, Mellins ED, Aiken RP. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol. 1993;20(1):118-122.
9. Foell D, Frosch M, Schulze zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Ann Rheum Dis. 2004;63(2):206-208.
10. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of lowdose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849-1857.
11. Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol. 1995;22(8):1574-1576.
12. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778.
13. Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics. 1997;100(6):994-997.
14. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43(3):628-637.
15. Schulze zur Wiesch A, Foell D, Frosch M, Vogl T, Sorg C, Roth J. Myeloid related proteins MRP8 /MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22(3):368-373.
16. Petty RE, Southwood TR, Manners P, et al; International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390
17. Hopewell S, Clarke M, Moher D, et al; CONSORT Group. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet. 2008;371(9609):281-283.
18. Bossuyt PM, Reitsma JB; Standards for Reporting of Diagnostic Accuracy. The STARD initiative. Lancet. 2003;361(9351):71.
19. Foell D, Frosch M, Sorg C, Roth J. Phagocytespecific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344(1-2):37-51.
20. Ruperto N, Ravelli A, Cuttica R, et al; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum. 2005;52(9):2854-2864.
21. LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics. 1992;48(2):411-425.
22. Frosch M, Ahlmann M, Vogl T, et al. The myeloidrelated proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(3):883-891.
23. Wulffraat NM, Haas PJ, Frosch M, et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. Ann Rheum Dis. 2003;62(3):236-241.
24. van Lent PL, Grevers L, Blom AB, et al. Myeloidrelated proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigeninduced arthritis. Ann Rheum Dis. 2008;67(12):1750-1758.
25. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13(9):1042-1049.
26. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a "DAMP" view of inflammatory arthritis. Nat Clin Pract Rheumatol. 2007;3(7):382-390.
27. Björk P, Björk A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7(4):e97.
28. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci. 2006;51(9):1516-1524.
29. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping secondline drugs in rheumatoid arthritis. Lancet. 1996;347(8998):347-352.
30. Greene MT, Whitington PF. Outcomes in pediatric autoimmune hepatitis. Curr Gastroenterol Rep. 2009;11(3):248-251.